Context: Research on factors that influence prescribing patterns and the extent of change produced by clinical trial findings is limited.
Objective: To examine the changes in prescribing of alpha-blockers for hypertension treatment before and after the April 2000 publication of the unfavorable Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) early termination involving the study's doxazosin mesylate arm. Changes in prescribing were considered in the context of other potential concurrent influences on medication use between 1996 and 2002, including changes in alpha-blocker drug prices, generic conversion, drug promotion, and competition.
Design, Setting, And Patients: Using 2 national pharmaceutical market research reports published by IMS HEALTH, alpha-blocker prescription orders reported in the National Prescription Audit-a random computerized sample of about 20 000 of 29 000 retail, independent, and mail order pharmacies and mass merchandise and discount houses--and office-based physician alpha-blocker prescribing patterns reported in the National Disease and Therapeutic Index--a random stratified sample of about 3500 physician offices--were tracked.
Outcome Measures: Trends in physician-reported use of alpha-blockers and alpha-blocker prescribing and dispensing by US pharmacies.
Results: There were steady increases in alpha-blocker new prescriptions, dispensed prescriptions, and physician drug use from 1996 through 1999. There was a moderate reversal in these trends following ALLHAT early termination and subsequent publications in early 2000. Between 1999 and 2002, new annual alpha-blocker prescription orders declined by 26% (from 5.15 million to 3.79 million), dispensed prescriptions by 22% (from 17.2 million to 13.4 million), and physician-reported drug use by 54% (from 2.26 million to 1.03 million). Other potential influences did not appear to have contributed significantly to this decline although cessation of alpha-blocker marketing may have hastened the decline.
Conclusions: Modest yet statistically significant declines in the use of doxazosin and other alpha-blockers coincided with the early termination of the ALLHAT doxazosin arm. Although physicians responded to this new evidence, strategies to augment the impact of clinical trials on clinical practice are warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.291.1.54 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phytomedicines in Pharmacotherapy of LUTS/BPH - What Do Patients Think?
Patient Prefer Adherence
December 2024
Department of Urology, University Hospital, LMU Munich, Munich, Germany.
Article Synopsis
- The study focuses on lower urinary tract symptoms (LUTS) and the rising interest in phytomedicines as alternatives to traditional medications, especially with limited efficacy of current treatments.
- A survey conducted with 300 patients revealed that a significant portion (41%) of those on medication for LUTS were also using phytomedicines, which showed good tolerability despite lower efficacy ratings.
- Patients expressed a desire for insurance coverage for phytomedicines, highlighting a shift toward individualized treatment options and the importance of patient empowerment in the decision-making process.
Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.
BMC Nephrol
December 2024
Department of Nephrology, Graduate School of Medicine, Nagoya University, Tsurumai-Cho 65, Showa-Ku, Nagoya City, Aichi Prefecture, Japan.
Article Synopsis
- Alpha blockers (ABs) are commonly given to patients with chronic kidney disease (CKD) who often deal with high blood pressure, but the link between ABs and fracture risk is unclear, prompting this study.
- The research analyzed a large cohort from a Japanese medical database, focusing on patients newly prescribed either ABs for hypertension or non-AB antihypertensive medications, with separate analyses for males and females.
- The findings showed that while males had no increased fracture risk with AB use, females using ABs for voiding dysfunction exhibited a significant rise in fracture risk compared to those on antihypertensive ABs.
Background And Objectives: This study aimed to determine whether there is an association between the use of α-blockers to treat benign prostatic hyperplasia (BPH) and the development of heart failure in elderly Asian patients.
Materials And Methods: An Elderly Cohort Database of the National Health Insurance Service was used to select 22,540 patients with newly diagnosed BPH between January 1, 2008, and December 31, 2018. They were divided into two equal groups, one prescribed α-blockers and one not.
Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.
J Pediatr Gastroenterol Nutr
December 2024
Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Article Synopsis
- A study on infants with cystic fibrosis (CF) examined the impact of acid blocker therapy (ABT) on growth, gut microbiome (GM), and early lung disease, finding that over half of the participants used ABT by age 3.* -
- Although ABT use was more prevalent among children with pancreatic insufficiency, it did not lead to significant growth improvements; instead, it was linked to lower GM diversity and more severe lung disease.* -
- The research highlights the need for careful evaluation of ABT's risks and benefits, suggesting that current treatment guidelines for young children with CF require reevaluation.*
Tadalafil use is associated with a lower incidence of Type 2 diabetes in men with benign prostatic hyperplasia: A population-based cohort study.
J Intern Med
November 2024
Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan.
Article Synopsis
- - Tadalafil, typically used for benign prostatic hyperplasia (BPH), may also lower the risk of Type 2 diabetes mellitus (T2DM) in patients without prior diabetes.
- - A study compared 5,180 men who used tadalafil to 20,049 men who used alpha-blockers, finding that tadalafil users had a significantly lower incidence of T2DM over a median follow-up of about 27 months.
- - The results suggest that tadalafil is associated with a 53% reduction in the risk of developing T2DM compared to alpha-blockers, indicating it might be a better option for preventing diabetes in BPH patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!